Want to see SE:DPHA full AI Analyst Report?
DPHA Stock Chart & Stats
kr1.40
-kr0.02(-1.33%)
At close: 4:00 PM EDT
kr1.40
-kr0.02(-1.33%)
Day’s Range― - ―
52-Week Rangekr0.88 - kr27.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)44.15K
Market Cap
kr62.33M
Enterprise Value-kr1.84
Total Cash (Recent Filing)kr40.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.07
Shares Outstanding44,588,066
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt limits interest obligations and refinancing risk, giving Guard greater financial flexibility while it advances clinical programs, although this strength does not eliminate its need for external funding.
Reduced Operating LossThe smaller trailing loss may indicate some expense control or reduced operating burn. If sustained, this could extend the company’s funding runway and improve the economics of advancing its pipeline.
Focused Kidney-injury PipelineA concentrated focus on acute kidney injury gives the company a clear development identity and targets serious complications in high-risk clinical settings, where successful therapies could address substantial unmet medical needs.
Bears Say
No Reported RevenueThe absence of reported revenue confirms that Guard has not yet demonstrated commercial traction or a self-sustaining business model. Future value therefore depends heavily on clinical progress, approvals, and eventual partnering or product sales.
Large Persistent LossesMaterial ongoing losses indicate that the company remains in a capital-intensive development phase without operating profitability. Continued losses can constrain strategic flexibility and make successful clinical execution increasingly dependent on investor support.
Heavy Cash Burn And Shrinking EquityPersistent negative cash flow means operations cannot currently fund themselves, while the shrinking equity base signals accumulated losses and possible dilution. This creates recurring financing risk as clinical programs require further investment.
DPHA FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr0.88 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr62.33M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Currently, no data Available
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 44,588,066 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:DPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Technical Analysis
OncoZenge AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
Modus Therapeutics Holding AB
―
Spago Nanomedical AB
―